文献速递神经肿瘤

11C-蛋氨酸正电子发射断层显像描绘儿童高级别胶质瘤中非对比增强但高复发风险的肿瘤区域

11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma.
PubMed 文献 · J Neurooncol · 2017-01-11

研究评估了11C-蛋氨酸正电子发射断层显像(MET-PET)在31例儿童高级别胶质瘤中的预后价值,共62次MET-PET检查。MET-PET与MRI序列的一致性因序列而异,初始MET-PET区域与90%病例的复发肿瘤重叠。当非对比增强肿瘤(NCET)比例>10%时,进展时间更早(5.8个月 vs 10.5个月,p=0.035)。

要点

  • MET-PET可描绘儿童高级别胶质瘤复发风险增高的区域。
  • NCET比例>10%者进展时间更早(5.8个月 vs 10.5个月,p=0.035)。
  • 初始MET-PET区域与90%病例的复发肿瘤重叠。

核心结论

  • MET-PET可描绘复发风险增高的区域,可能改善失败定义、预后评估和放疗靶区定义。

研究设计与样本

  • 研究纳入31例儿童高级别胶质瘤患者,共进行62次MET-PET检查,评估MET-PET摄取与MRI肿瘤体积的一致性及预后影响。

主要发现

  • MET-PET与MRI序列的一致性因序列而异,多数病例中MET-PET对肿瘤体积的补充有限。
  • 标准化摄取值>3.0的MET-PET体积在诊断时、治疗后和复发时分布不同。
  • 初始MET-PET区域与90%病例的复发肿瘤重叠。
  • NCET比例>10%时,进展时间更早(5.8个月;95% CI 1-8.2 vs 10.5个月;95% CI 0.9-NR;p=0.035)。

关键数值与推荐

  • NCET定义为FLAIR显示不强化但MET-PET摄取阳性的肿瘤区域。
  • NCET比例>10%与更早进展相关(5.8个月 vs 10.5个月,p=0.035)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We assessed the prognostic utility of 11C-Methionine positron emission tomography (MET-PET) in pediatric high-grade glioma (HGG). Thirty-one children had 62 MET-PET studies. Segmented tumor volumes from co-registered magnetic resonance studies were assessed for concordance with MET-PET uptake using Boolean operations. The tumor volume at diagnosis and treatment failure was assessed relative to MET-PET avid volume. The prognostic impact of MET-PET-delineated non-contrast enhancing tumor (NCET) was assessed. NCET was defined as the region of tumor defined by defined by FLAIR which did not enhance but showed MET-PET avidity. MET-PET concordance varied according to magnetic resonance sequence. MET-PET rarely added to the tumor volume in most cases. The volume of MET-PET with standardized uptake value >3.0 was differentially distributed at diagnosis, post treatment, and at recurrence. The initial MET-PET region overlapped with recurrent tumor in 90% of the cases. When the proportion of tumor which was NCET was >10%, an earlier time to progression (5.8 months; 95% CI, 1-8.2 vs. 10.5 months; 95% CI, 0.9-NR; p = 0.035) was noted. MET-PET delineates regions at increased risk for recurrence and may improve the definition of failure, prognostic assessment, and target definition for radiotherapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lucas JT, Serrano N, Kim H, et al. 11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma. J Neurooncol. 2017. PMID: 28078638. doi:10.1007/s11060-016-2354-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。